Manu Prasad

Beersheba, D, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Genomic Enrichment and Functional Impact of TP53 and CYLD Alterations in Recurrent and Metastatic HPV-Associated Head and Neck Cancer.

Genomic Enrichment and Functional Impact of TP53 and CYLD Alterations in Recurrent and Metastatic HPV-Associated Head and Neck Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 23, 2025

Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers.

Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers.

Journal: Neoplasia (New York, N.Y.)

Published: February 23, 2025

Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic dissemination.

Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic dissemination.

Journal: Nature genetics

Published: July 21, 2024

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer.

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 14, 2024

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.

Journal: Nature medicine

Published: February 02, 2023

Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.

Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.

Journal: Molecular oncology

Published: October 26, 2022

Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.

Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.

Journal: Cancer research

Published: August 16, 2022

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.

Journal: Journal for immunotherapy of cancer

Published: February 06, 2022

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma).

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma).

Journal: Cancers

Published: June 30, 2021

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.

Journal: Cancers

Published: March 25, 2021

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System.

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System.

Journal: Journal of visualized experiments : JoVE

Published: January 28, 2020

TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer.

TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer.

Journal: Cancers

Published: January 07, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026